Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Platelet Lysate for Ocular GVHD
NCT05311514Phase 2Completed
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Apr 2021
- Primary completion
- Nov 2024
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of allogeneic platelet lysate eye drops in ocular graft-versus-host disease (oGVHD) (2 arms), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Response of ocular chronic GVHD at 2 years. Started Apr 2021; status: completed.
02
Drugs
allogeneic platelet lysate eye drops
03
Conditions
ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT05311514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311514.